Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
52°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
Photos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Novo Nordisk A/S ADR
(NY:
NVO
)
118.01
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, Oct 1, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
7,900
Open
118.01
Bid (Size)
117.20 (4)
Ask (Size)
117.28 (3)
Prev. Close
118.01
Today's Range
118.01 - 118.01
52wk Range
86.96 - 148.15
Shares Outstanding
N/A
Dividend Yield
1.50%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
US HHS Reveal Cost Savings For 54 Prescription Drugs Including Novartis' Cancer Drug, Ozempic Could be Next
October 01, 2024
HHS announced lower costs for 54 Medicare Part B drugs starting in October 2024, part of the Inflation Reduction Act's rebate program, which aims to curb rising drug prices and reduce out-of-pocket...
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition
October 01, 2024
Via
Investor Brand Network
Performance
YTD
+15.57%
+15.57%
1 Month
-13.39%
-13.39%
3 Month
-17.46%
-17.46%
6 Month
-6.68%
-6.68%
1 Year
+28.55%
+28.55%
More News
Read More
Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition
October 01, 2024
Via
FinancialNewsMedia
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $4,700 Today
September 27, 2024
Via
Benzinga
Novo Nordisk's Options: A Look at What the Big Money is Thinking
September 24, 2024
Via
Benzinga
Roche Fast-Tracks Obesity Drug Development, Eyes Over $3B Sales Potential
September 30, 2024
Via
Benzinga
Investors should take note of NYSE:NVO, a growth stock that remains attractively priced.
September 30, 2024
Via
Chartmill
'Stop Ripping Us Off' – Incredibly, Elon Musk And Bernie Sanders Seem To Agree On This One Thing – 'I Really Am With Bernie On This One'
September 29, 2024
Via
Benzinga
Success in This New Battleground Could Make Eli Lilly and Novo Nordisk Stock Absolutely Fly for Years
September 28, 2024
Via
The Motley Fool
Benzinga Bulls And Bears: Apple, Tesla, Novo Nordisk, Bitcoin — And Shiba Inu's Major Stablecoin Tease
September 28, 2024
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Latest Inflation Data Cements Fed's Interest Rate Call, S&P 500 Hits All-Time High, Biden Adviser Backs China EV Ban At Detroit Economic Club: This Week In The Markets
September 27, 2024
Via
Benzinga
Topics
Artificial Intelligence
Economy
Stocks
Exposures
Artificial Intelligence
Interest Rates
US Equities
Novo Nordisk Slips On Analyst Warning Of Weaker Wegovy Sales
September 27, 2024
Via
Investor's Business Daily
Cassava Sciences, enVVeno Medical And Other Big Stocks Moving Lower In Friday's Pre-Market Session
September 27, 2024
Via
Benzinga
Novo Nordisk Just Committed More Than $1.1 Billion to Make the Next Ozempic, but Is the Stock a Buy?
September 27, 2024
Via
The Motley Fool
Novo Nordisk And Evotec Collaborate On Stem Cell-Based Therapy Development
September 26, 2024
Via
Benzinga
Forget Novo Nordisk, Buy This Magnificent Dividend Stock Instead
September 26, 2024
Via
The Motley Fool
EXCLUSIVE: Vivani Medical Advances Its Obesity Treatment Implant With New Clinical Trial in Australia
September 26, 2024
Via
Benzinga
Novo Nordisk's $600 Million Gambit Could Be a Game Changer for the Stock. Here's Why.
September 26, 2024
Via
The Motley Fool
Lose Weight With Novo Nordisk Drugs, Gain Money With Stock
September 25, 2024
Via
Benzinga
Popular Ozempic May Have New Use As Semaglutide Drugs Linked To Reduced Overdose Risk In Diabetic Opioid Users
September 25, 2024
Via
Benzinga
Can Novo Nordisk's Weight Loss Drug Ozempic Help Stem The Devastating Addiction Crisis? New Research Says Yes
September 25, 2024
Via
Benzinga
Bristol Myers-2seventy Bio Halt Phase 3 Trial For Abecma In Newly Diagnosed Myeloma Patients, Speeds Path To Profitability
September 25, 2024
Via
Benzinga
Exposures
Product Safety
EXCLUSIVE: Novo Nordisk Faces Political Heat Over Weight-Loss Drug Prices Ahead Of Elections, Yet 'The Real Issue Is With The Middlemen'
September 25, 2024
Via
Benzinga
Novo Nordisk To Consider Ways For Patients To Affordably Access Weight Loss Drugs Ozempic, Wegovy, Says CEO
September 24, 2024
Via
Benzinga
Novo Nordisk’s Setback Won’t Last: A Game-Changing Drug Emerges
September 24, 2024
Via
MarketBeat
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.